We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




High-Resolution Cancer Virus Imaging Uncovers Potential Therapeutic Targets

By LabMedica International staff writers
Posted on 18 Feb 2026

Human T-cell leukemia virus (HTLV) is a retrovirus that causes adult T-cell leukemia/lymphoma, a serious blood cancer with no approved treatment. More...

Although related to HIV, HTLV remains less understood at the molecular level, limiting the development of targeted therapies. Understanding how the virus assembles and spreads is critical for designing effective antiviral strategies. Now, new research provides high-resolution structural insights into the virus, revealing potential targets for future treatment development.

In a study led by the University of Minnesota School of Dentistry and Masonic Cancer Center (Minneapolis, MN, USA), in collaboration with the Institute for Molecular Virology (Minneapolis, MN, USA), researchers used cryogenic transmission electron microscopy and tomography to examine the HTLV capsid protein. Cryo-EM/ET enables detailed three-dimensional imaging by rapidly freezing viral samples at extremely low temperatures. The capsid protein, which forms the protective shell around the virus’s genetic material, plays a central role in viral assembly and represents a promising therapeutic target.

Using cryo-EM/ET, researchers successfully visualized the capsid protein’s structure and identified key features of viral assembly. For the first time, they measured the spatial relationship between the capsid protein and the virus’s outer layer, providing insight into capsid distribution within viral particles. The team also discovered that a negatively charged molecule known to assist HIV particle formation can interact with HTLV but is not required for its assembly. The findings, published in Nature Communications, highlight structural differences that could inform targeted drug design.

The detailed structural maps may support structure-based drug development strategies similar to those successfully used in HIV therapy. By clarifying how the capsid protein contributes to viral assembly and infectivity, the research offers a foundation for identifying compounds that disrupt this process. Future work will focus on understanding how HTLV spreads through direct cell-to-cell contact and determining how antiviral agents could interfere with capsid formation and viral replication.

“These high-resolution images will be useful for helping us understand why HTLV infectivity is strongly correlated with being associated with cells, where virus spread occurs through direct cell-to-cell contact,” said Louis Mansky, co-lead investigator of the study. “This remains a long-standing question in the field and could help guide the design of treatments for HTLV infection — a highly important task, knowing there are currently no such approved therapeutics.”

Related Links:
University of Minnesota School of Dentistry
Institute for Molecular Virology


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
All-in-One Molecular System
AIO M160
New
POC Immunoassay Analyzer
Procise DX
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.